Posted by Michael Wonder on 21 Dec 2023
RemeGen announces continued inclusion of telitacicept and disitamab vedotin in China National Reimbursement Drug List, ensuring continuous accessibility of innovative drugs for more patients
18 December 2023 - RemeGen has recently confirmed that under the 2023 simple renewal mechanism of China National Healthcare Security Administration, on 1 January 2024, the updated National Reimbursement Drug List will continue to include telitacicept and disitamab vedotin for the next two year agreement.
